Videos

Drs Javle, Bañales, and Hollebecque discuss the innate and acquired resistance pathways to FGFR inhibitors in cholangiocarcinoma and how these pathways can have important effects on clinical outcomes. They also look ahead to ongoing clinical trials evaluating next-generation FGFR inhibitors that may be able to overcome resistance mechanisms and improve progression-free and overall survival in cholangiocarcinoma.

Richard Kim, MD, from the Moffitt Cancer Center, University of South Florida College of Medicine, provides expert commentary on key abstracts and posters presented at the 2021 annual meeting of the European Society for Medical Oncology. Dr Kim will highlight new data from 11 presentations on interventional modalities for patients with cholangiocarcinoma.

Advantages and disadvantages of liquid biopsy in CCA

Rational choices for combination therapy in CCA

Flavio G. Rocha, MD, FACS, FSSO, from the Knight Cancer Institute, Oregon Health & Science University, provides expert commentary on key abstracts and posters presented at the 2021 annual meeting of the Americas Hepato-Pancreato-Biliary Association. Dr Rocha will highlight new data from 10 presentations on interventional modalities for patients with cholangiocarcinoma.

Using next-generation sequencing to detect FGFR fusion partners and co-mutations to improve efficacy in treating CCA

Evaluating the impact of FGFR inhibitors on the quality of life in patients with CCA

On June 8, 2021, Dr Mitesh Borad, Associate Professor of Medicine at the Mayo Clinic in Phoenix, AZ, and a member of the Cholangiocarcinoma Summit Program Steering Committee, presented the top 15 abstracts on the management of cholangiocarcinoma and biliary tract cancer at ASCO 2021.

Managing hyperphosphatemia and RPED in patients treated with FGFR inhibitors